Tag: allogeneic MSC therapy for GVHD

Home / allogeneic MSC therapy for GVHD

Categories

Remestemcel-L-rknd is approved by the USFDA for steroid-refractory acute graft versus host disease in pediatric patients

On December 18, 2024, the Food and Drug Administration sanctioned remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-r...
allogeneic-msc-therapy-for-gvhd

Scan the code